Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer

Pernelle Lavaud; Clément Dumont; Constance Thibault; Laurence Albiges; Giulia Baciarello; Emeline Colomba; Ronan Flippot; Alina Fuerea; Yohann Loriot; Karim Fizazi

doi:10.1177/1758835920978134

Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer

Pernelle Lavaud, Clément Dumont, Constance Thibault, Laurence Albiges, Giulia Baciarello, Emeline Colomba, Ronan Flippot, Alina Fuerea, Yohann Loriot, Karim Fizazi

Résultats de recherche: Contribution à un journal › Article 'review' › Revue par des pairs

13 Citations (Scopus)

Résumé

Until recently, continuing androgen deprivation therapy (ADT) and closely monitoring patients until evolution towards metastatic castration-resistant prostate cancer (CRPC) were recommended in men with non-metastatic CRPC (nmCRPC). Because delaying the development of metastases and symptoms in these patients is a major issue, several trials have investigated next-generation androgen receptor (AR) axis inhibitors such as apalutamide, darolutamide, and enzalutamide in this setting. This review summarizes the recent advances in the management of nmCRPC, highlighting the favourable impact of next-generation AR inhibitors on metastases-free survival, overall survival and other clinically meaningful endpoints.

langue originale	Anglais
journal	Therapeutic Advances in Medical Oncology
Volume	12
Les DOIs	https://doi.org/10.1177/1758835920978134
état	Publié - 1 janv. 2020

Accès au document

10.1177/1758835920978134

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{cf1d9668f5cc4cb4920041127340a8e7,

title = "Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer",

abstract = "Until recently, continuing androgen deprivation therapy (ADT) and closely monitoring patients until evolution towards metastatic castration-resistant prostate cancer (CRPC) were recommended in men with non-metastatic CRPC (nmCRPC). Because delaying the development of metastases and symptoms in these patients is a major issue, several trials have investigated next-generation androgen receptor (AR) axis inhibitors such as apalutamide, darolutamide, and enzalutamide in this setting. This review summarizes the recent advances in the management of nmCRPC, highlighting the favourable impact of next-generation AR inhibitors on metastases-free survival, overall survival and other clinically meaningful endpoints.",

keywords = "apalutamide, castration resistance, darolutamide, enzalutamide, next generation androgen receptor inhibitors, non-metastatic setting, prostate cancer",

author = "Pernelle Lavaud and Cl{\'e}ment Dumont and Constance Thibault and Laurence Albiges and Giulia Baciarello and Emeline Colomba and Ronan Flippot and Alina Fuerea and Yohann Loriot and Karim Fizazi",

note = "Publisher Copyright: {\textcopyright} The Author(s), 2020.",

year = "2020",

month = jan,

day = "1",

doi = "10.1177/1758835920978134",

language = "English",

volume = "12",

journal = "Therapeutic Advances in Medical Oncology",

issn = "1758-8340",

}

TY - JOUR

T1 - Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer

AU - Lavaud, Pernelle

AU - Dumont, Clément

AU - Thibault, Constance

AU - Albiges, Laurence

AU - Baciarello, Giulia

AU - Colomba, Emeline

AU - Flippot, Ronan

AU - Fuerea, Alina

AU - Loriot, Yohann

AU - Fizazi, Karim

N1 - Publisher Copyright: © The Author(s), 2020.

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Until recently, continuing androgen deprivation therapy (ADT) and closely monitoring patients until evolution towards metastatic castration-resistant prostate cancer (CRPC) were recommended in men with non-metastatic CRPC (nmCRPC). Because delaying the development of metastases and symptoms in these patients is a major issue, several trials have investigated next-generation androgen receptor (AR) axis inhibitors such as apalutamide, darolutamide, and enzalutamide in this setting. This review summarizes the recent advances in the management of nmCRPC, highlighting the favourable impact of next-generation AR inhibitors on metastases-free survival, overall survival and other clinically meaningful endpoints.

AB - Until recently, continuing androgen deprivation therapy (ADT) and closely monitoring patients until evolution towards metastatic castration-resistant prostate cancer (CRPC) were recommended in men with non-metastatic CRPC (nmCRPC). Because delaying the development of metastases and symptoms in these patients is a major issue, several trials have investigated next-generation androgen receptor (AR) axis inhibitors such as apalutamide, darolutamide, and enzalutamide in this setting. This review summarizes the recent advances in the management of nmCRPC, highlighting the favourable impact of next-generation AR inhibitors on metastases-free survival, overall survival and other clinically meaningful endpoints.

KW - apalutamide

KW - castration resistance

KW - darolutamide

KW - enzalutamide

KW - next generation androgen receptor inhibitors

KW - non-metastatic setting

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85097988414&partnerID=8YFLogxK

U2 - 10.1177/1758835920978134

DO - 10.1177/1758835920978134

M3 - Review article

AN - SCOPUS:85097988414

SN - 1758-8340

VL - 12

JO - Therapeutic Advances in Medical Oncology

JF - Therapeutic Advances in Medical Oncology

ER -